← Leaderboards
Christopher J Tignanelli
Yale University
$1,538,661
Attributed
$3,077,322
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $985.4K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
AHRQ$2,937,874 · 1
NIH$139,448 · 1
By mechanism
R18$2,937,874 · 1
R00$139,448 · 1
Top collaborators
- Genevieve B Melton-Meaux3 shared
- Morgan Elyse Levine1 shared
Most similar at Yale University
Same institution · by research overlap
- George B Richerson$18,281,692
- Harriet M Kluger$18,066,555
- Holly Gwen Prigerson$25,326,202
- Anthony N Van Den Pol$25,732,423
- Kathleen Ann Martin$14,895,788
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultAge RelatedAgingAllelesBaseBiologicalBiological AgingBiological MarkersBisulfiteCardiovascular DiseasesCellsCell TypeCenters For Disease Control And Prevention (U.S.)Cessation Of LifeChronic DiseaseChronic Kidney FailureChronic Obstructive Airway DiseaseChronologyClinicClinical ApplicationClinical RiskCommunitiesCoronavirus DiseaseAdmission Activity
Grant awards (4)
Evaluation of the SCALED (SCaling AcceptabLE cDs) Approach for the Implementation of Interoperable CDS for Venous Thromboembolism Prevention$974,802
R18 · FY2024 · HS · contact PI
Evaluation of the SCALED (SCaling AcceptabLE cDs) Approach for the Implementation of Interoperable CDS for Venous Thromboembolism Prevention$977,689
R18 · FY2023 · HS · contact PI
Evaluation of the SCALED (SCaling AcceptabLE cDs) Approach for the Implementation of Interoperable CDS for Venous Thromboembolism Prevention$985,383
R18 · FY2022 · HS · contact PI
Epigenetic Age Measures to Predict COVID-19 Symptom Progression and Severity$139,448
R00 · FY2020 · AG